Search

Your search keyword '"Locaputo S."' showing total 6 results
Start Over Author "Locaputo S." Topic male
6 results on '"Locaputo S."'

1. Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015

Author

Quiros-Roldan, E., Magro, P., Raffetti, E., Izzo, I., Borghetti, Alberto, Lombardi, Francesca, Saracino, A., Maggiolo, F., Castelli, F., Carosi, Giulia, Paraninfo, G. E., Torti, Carlo, Cauda, Roberto, Di Giambenedetto, Simona, Fabbiani, M., Colafigli, Manuela, Scalzini, A., Castelnuovo, F., El Hamad, I., Mazzotta, F., Locaputo, S., Marino, N., Pierotti, P., Di Pietro, Maria Luisa, Ble, C., Vichi, F., Sighinolfi, L., Angarano, G., Ladisa, N., Monno, L., Maggi, P., Pan, A., Costarelli, S., Gori, A., Lapadula, G., Puoti, M., Viale, P., Colangeli, V., Borderi, M., Quiros-Roldan, E, Magro, P, Raffetti, E, Izzo, I, Borghetti, A, Lombardi, F, Saracino, A, Maggiolo, F, Castelli, F, Carosi, G, Paraninfo, G, Torti, C, Cauda, R, Di Giambenedetto, S, Fabbiani, M, Colafigli, M, Scalzini, A, Castelnuovo, F, El Hamad, I, Mazzotta, F, Locaputo, S, Marino, N, Pierotti, P, Di Pietro, M, Ble, C, Vichi, F, Sighinolfi, L, Angarano, G, Ladisa, N, Monno, L, Maggi, P, Pan, A, Costarelli, S, Gori, A, Lapadula, G, Puoti, M, Viale, P, Colangeli, V, Borderi, M, Blè, C, and Border, M

Subjects
0301 basic medicine, Male, HIV Infections, Gastroenterology, Cohort Studies, 0302 clinical medicine, Abacavir, Antiretroviral Therapy, Highly Active, 030212 general & internal medicine, Darunavir, virus diseases, Switch, Middle Aged, Antiretroviral therapy, Infectious Diseases, Treatment Outcome, Italy, Reverse Transcriptase Inhibitors, Female, medicine.symptom, medicine.drug, Research Article, Adult, medicine.medical_specialty, Anti-HIV Agents, Dual-therapy, HIV, Inflammation, Atazanavir Sulfate, CD4-CD8 Ratio, Renal function, Settore MED/17 - MALATTIE INFETTIVE, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, Immune system, Internal medicine, medicine, Humans, lcsh:RC109-216, Tenofovir, Retrospective Studies, business.industry, Retrospective cohort study, Reverse transcriptase, Dideoxynucleosides, Regimen, 030104 developmental biology, business, CD8
Abstract

Background Triple-drug regimens are the gold standard for HIV therapy. Nucleos(t)ide reverse transcriptase inhibitors (NRTIs) reducing regimens are used to decrease drugs toxicity, exposure and costs. Aim of our study was to evaluate trends of biochemical and inflammatory indices in patients switching to dual therapy (DT). Methods We included patients that a) switched to a DT from 2007 to 2015 from a tenofovir/abacavir-based triple regimen b) previously maintained a triple and c) subsequently a dual regimen for 12 months with virological suppression. We retrieved data measured at 5 points (at the switch, 6 and 12 months before and after switch). We used platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR) and CD4/CD8 ratio as inflammatory indices. We assessed temporal trends of viro-immunological, biochemical and inflammatory parameters. Results Overall, 364 and 65 patients switched from a tenofovir- and an abacavir-triple regimen, respectively. In the tenofovir-reducing group, creatinine clearance and lipids raised after the switch. There was a significant increase in both CD4+ cells and CD4/CD8. CD8+ cells rose after the switch, while opposite trend was found for PLR. In the abacavir-reducing group total lipids showed a decrease during the first 6 months after the switch and then stabilized. An increase of CD4+ and a decrease of CD8+ cells was observed during the study period, although not statistically significant. While CD4/CD8 remained stable after simplification, PLR decreased significantly after 6 months, then returning to baseline. CD8+ cells increased in the tenofovir-reducing group despite a viro-immunological response. Intriguingly, PLR decreased, maintaining this trend for 12 and 6 months after tenofovir and abacavir interruption respectively. Conclusions Increased PLR has been linked to hypercholesterolemia and metabolic-syndrome, while high CD8+ cells count to increased risk of non-AIDS-related events regardless of CD4 T-cell recovery and to virological failure. Whether these findings may have clinical implications, and which role DT plays on the immune system and on inflammation should be further investigated.

Published
2018

2. Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART

Author

LAPADULA, GIUSEPPE, GORI, ANDREA, Chatenoud, L, Castelli, F, Di Giambenedetto, S, Fabbiani, M, Maggiolo, F, Focà, E, Ladisa, N, Sighinolfi, L, Di Pietro, M, Pan, A, Torti, C, Carosi, G, Quiros, E, Nasta, P, Paraninfo, G, Cauda, R, Colafigli, M, Scalzini, A, Castelnuovo, F, El Hamad, I, Mazzotta, F, Locaputo, S, Pierotti, P, Marino, N, Blè, C, Vichi, F, Angarano, G, Monno, L, Maggi, P, Costarelli, S, Puoti, M, Viale, P, Colangeli, V, Borderi, M., Lapadula, G, Chatenoud, L, Gori, A, Castelli, F, Di Giambenedetto, S, Fabbiani, M, Maggiolo, F, Focà, E, Ladisa, N, Sighinolfi, L, Di Pietro, M, Pan, A, Torti, C, Carosi, G, Quiros, E, Nasta, P, Paraninfo, G, Cauda, R, Colafigli, M, Scalzini, A, Castelnuovo, F, El Hamad, I, Mazzotta, F, Locaputo, S, Pierotti, P, Marino, N, Blè, C, Vichi, F, Angarano, G, Monno, L, Maggi, P, Costarelli, S, Puoti, M, Viale, P, Colangeli, V, Borderi, M, Lapadula, G., Chatenoud, L., Gori, A., Castelli, F., Di Giambenedetto, S., Fabbiani, M., Maggiolo, F., Foca, E., Ladisa, N., Sighinolfi, L., Di Pietro, M., Pan, A., Torti, C., Carosi, G., Quiros, E., Nasta, P., Paraninfo, G., Cauda, R., Colafigli, M., Scalzini, A., Castelnuovo, F., El Hamad, I., Mazzotta, F., Locaputo, S., Pierotti, P., Marino, N., Ble, C., Vichi, F., Angarano, G., Monno, L., Maggi, P., Costarelli, S., Puoti, M., Viale, P., Colangeli, V., and Borderi, M.

Subjects
Male, Comorbidity, medicine.disease_cause, Risk Factors, Neoplasms, Antiretroviral Therapy, Highly Active, Cardiovascular Disease, education.field_of_study, Multidisciplinary, Coinfection, Incidence (epidemiology), Liver Diseases, Liver Disease, Medicine (all), Hepatitis C, Middle Aged, Viral Load, Cardiovascular Diseases, Disease Progression, Medicine, Female, Viral load, Research Article, Human, Adult, medicine.medical_specialty, Science, Hepatitis C virus, Population, Antiretroviral Therapy, Settore MED/17 - MALATTIE INFETTIVE, Acquired immunodeficiency syndrome (AIDS), Internal medicine, medicine, Humans, Highly Active, education, Acquired Immunodeficiency Syndrome, Biochemistry, Genetics and Molecular Biology (all), business.industry, Risk Factor, medicine.disease, CD4 Lymphocyte Count, cd4, Agricultural and Biological Sciences (all), Immunology, Neoplasm, business
Abstract

Background: Immunological non-response (INR) despite virological suppression is associated with AIDS-defining events/death (ADE). Little is known about its association with serious non-AIDS-defining events (nADE). Methods Patients highly-active antiretroviral therapy (HAART) with 50. Results: 1221 patients were observed for a median of 3 (IQR: 1.3-6.1) years. Pre-HAART CD4+were 77/μl (IQR: 28-142) and 56% of patients had experienced an ADE. After 1 year, CD4+ increased to 286 (IQR: 197-387), but 26.1% of patients were INR. Thereafter, 86 nADE (30.2% malignancies, 27.9%infectious, 17.4%renal, 17.4Êrdiovascular, 7% hepatic) were observed, accounting for an incidence of 1.83 events (95%CI: 1.73-2.61) per 100 PYFU. After adjusting for measurable confounders, INR had a significantly greater risk of nADE (HR 1.65; 95%CI: 1.06-2.56). Older age (per year, HR 1.03; 95%CI: 1.01-1.05), hepatitis C co-infection (HR 2.09; 95%CI: 1.19-3.7), a history of previous nADE (HR 2.16; 95% CI: 1.06-4.4) and the occurrence of ADE during the follow-up (HR 2.2; 95%CI: 1.15-4.21) were other independent predictors of newly diagnosed nADE. Conclusions: Patients failing to restore CD4+ to >200 cells/μl run a greater risk of serious nADE, which is intertwined or predicted by AIDS progression. Improved management of this fragile population and innovative therapy able to induce immune-reconstitution are urgently needed. Also, our results strengthen the importance of earlier diagnosis and HAART introduction.

Published
2015

3. Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort

Author

Postorino, M. C, Prosperi, M., QUIROS ROLDAN, Maria Eugenia, Maggiolo, F., Di Giambenedetto, S., Saracino, A., Costarelli, S., Lorenzotti, S., Sighinolfi, L., Di Pietro, M., Torti, Carlo, Castelli, Francesco, Carosi, Giampiero, Nasta, Paola, Paraninfo, G., Foca', Emanuele, Torti, C., Cauda, R., Fabbiani, M., Colafigli, M., Scalzini, Alfredo, Castelnuovo, F., Mazzotta, F., Locaputo, S., Marino, N., Pierotti, P., Ble, C., Vichi, F., Angarano, G., Ladisa, N., Monno, L., Maggi, Paolo, Pan, A., Gori, A., Lapadula, G., Ospedale, S., Puoti, M., Viale, P., Colangeli, V., Borderi, M., Policlinico, S., Postorino, M. C., Prosperi, M., Quiros-Roldan, E., Maggiolo, F., Di Giambenedetto, S., Saracino, A., Costarelli, S., Lorenzotti, S., Sighinolfi, L., Di Pietro, M., Torti, C., Castelli, F., Carosi, G., Nasta, P., Paraninfo, G., Foca, E., Cauda, R., Fabbiani, M., Colafigli, M., Scalzini, A., Castelnuovo, F., Mazzotta, F., Locaputo, S., Marino, N., Pierotti, P., Ble, C., Vichi, F., Angarano, G., Ladisa, N., Monno, L., Maggi, P., Pan, A., Gori, A., Lapadula, G., Ospedale, S., Puoti, M., Viale, P., Colangeli, V., Borderi, M., and Policlinico, S.

Subjects
Cyclopropanes, Male, AIDS event, HIV Infections, Cohort Studies, chemistry.chemical_compound, Antiretroviral Therapy, Highly Active, HIV Infection, Viral, immunological response, ritonavir-boosted protease inhibitors, composite outcome, virus diseases, Lopinavir, General Medicine, Hepatitis C, Middle Aged, Viral Load, non-nucleoside reverse transcriptase inhibitors, Death, Ritonavir-boosted protease inhibitor, Treatment Outcome, Infectious Diseases, Anti-Retroviral Agents, Italy, Alkynes, Cohort, RNA, Viral, Female, Viral load, Human, medicine.drug, Cohort study, Benzoxazine, Adult, Microbiology (medical), medicine.medical_specialty, Efavirenz, Atazanavir Sulfate, virological response, Antiretroviral Therapy, Non-nucleoside reverse transcriptase inhibitor, AIDS events, Composite outcome, Deaths, First-line therapy, Immunological response, Non-nucleoside reverse transcriptase inhibitors, Ritonavir-boosted protease inhibitors, Virological response, Benzoxazines, CD4 Lymphocyte Count, Humans, Ritonavir, Settore MED/17 - MALATTIE INFETTIVE, first-line therapy, Internal medicine, medicine, Highly Active, business.industry, Odds ratio, medicine.disease, deaths, chemistry, Immunology, RNA, Anti-Retroviral Agent, Cohort Studie, business
Abstract

Randomized trials and observational cohorts reported higher rates of virological suppression after highly active antiretroviral therapy (HAART) including efavirenz (EFV), compared with boosted protease inhibitors (PIs). Correlations with immunological and clinical outcomes are unclear. Patients of the Italian MASTER cohort who started HAART from 2000 to 2010 were selected. Outstanding outcome (composite outcome for success (COS)) was introduced. We evaluated predictors of COS (no AIDS plus CD4+ count >500/mm3 plus HIV-RNA

Published
2015

4. [Retinal lesions in HIV seropositive patients]

Author

BALACCO GABRIELI, Corrado, Angarano, G., Moramarco, Antonietta, Locaputo, S., Rasi, V., and Pacella, Elena

Subjects
Adult, Male, Acquired Immunodeficiency Syndrome, Retinal Hemorrhage, Retinal Vessels, human immunodeficiency virus infection, Middle Aged, retina vasculitis, retinopathy, Chorioretinitis, Retinal Diseases, Ischemia, HIV Seropositivity, Humans, Female, Follow-Up Studies
Abstract

118 patients with HIV infection underwent complete ophthalmologic examination to detect the presence of any eye pathology. The study was intended to show a correlation between such pathology and the total CD4 + lymphocyte count considered to be indicative of the immunologic status. The most frequently encountered lesions were cotton-wool patches, vascular congestion, hemorrhages, chorioretinitis, segmental vasculitis and optic disc pallar. Almost all the patients with ocular manifestations, also had a CD4 + count of less than 200/mm3 which suggest that ocular lesions are of bad prognostic significance even in asymptomatic patients.

Published
1989

5. Ocular manifestations in HIV-seropositive patients

Author

Balacco Gabrieli, C., Angarano, G., Antonietta MORAMARCO, Locaputo, S., and Castellano, L.

Subjects
Adult, CD4-Positive T-Lymphocytes, Male, Acquired Immunodeficiency Syndrome, Adolescent, Eye Diseases, Fundus Oculi, eye disease, fluorescence angiography, aids related complex, human immunodeficiency virus infection, Middle Aged, Leukocyte Count, AIDS-Related Complex, HIV Seropositivity, Humans, Female, Fluorescein Angiography
Abstract

A total of 153 patients with human immunodeficiency virus (HIV) infection underwent complete ophthalmologic examinations for the presence of any eye pathology. We wanted to show a correlation between such pathology and total CD4+ lymphocyte count, believed to be an indicator of immunologic status. The most frequently encountered lesions were cotton-wool patches, vascular congestion, hemorrhages, chorioretinitis, segmental vasculitis, and pallid papilla. Almost all of the patients with ocular anomalies also had a CD4+ count of less than 200 cells/mm3 suggesting that ocular lesions have a negative prognostic significance even in asymptomatic patients who present with a severe impairment of their immune system.

6. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study

Author

Francesco Mazzotta, Paolo Maggi, Filippo Castelnuovo, Carlo Torti, Francesca Moretti, Sergio Lo Caputo, Carmine Tinelli, Valeria Micheli, Nicoletta Ladisa, Anna Orani, Mario Regazzi, Andrea Patroni, Andrea Antinori, Eugenia Quiros-Roldan, Giampiero Carosi, Simona Di Giambenedetto, Paola Villani, Andrea De Luca, Torti, C, Quiros-Roldan, E, Regazzi, M, De Luca, A, Mazzotta, F, Antinori, A, Ladisa, N, Micheli, V, Orani, A, Patroni, A, Villani, P, Locaputo, S, Moretti, F, Di Giambenedetto, S, Castelnuovo, F, Maggi, P, Tinelli, C, and Carosi, G.

Subjects
Adult, Male, Microbiology (medical), medicine.medical_specialty, Genotype, Anti-HIV Agents, Salvage therapy, HIV Infections, Drug resistance, law.invention, Randomized controlled trial, law, Internal medicine, Drug Resistance, Viral, medicine, Humans, Trough Concentration, Sida, Salvage Therapy, biology, Reverse-transcriptase inhibitor, business.industry, Middle Aged, biology.organism_classification, Surgery, Regimen, Phenotype, Infectious Diseases, HIV-1, Female, Ritonavir, business, medicine.drug
Abstract

Background. It is not well defined whether concentration-controlled intervention (CCI) and rules-based human immunodeficiency virus (HIV) type 1 genotype drug-resistance interpretation (GI) or virtual phenotype drug-resistance interpretation (VPI) may improve the outcome of HIV salvage therapy. Methods. In a prospective, randomized, controlled trial, patients were randomized (on a factorial basis) to change treatment after either GI or VPI, and they then were further randomized to the control arm (no CCI) or the CCI arm. Protease inhibitor (PI) and nonnucleoside reverse-transcriptase inhibitor (NNRTI) trough concentration (C trough ) values were determined at weeks 1, 4, 12, and 24 of the study. Results. Among 230 patients, virological benefit (defined by an HIV RNA load of

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results